Related Experiment Video
Updated: Feb 14, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.2K
Repurposing anticancer drugs for targeting necroptosis
Simone Fulda1,2,3
1a Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt , Komturstrasse 3a, 60528 Frankfurt , Germany.
Cell Cycle (Georgetown, Tex.)
|February 22, 2018
Summary
Certain cancer drugs, like Dabrafenib and Vemurafenib, can inhibit necroptosis, a programmed cell death pathway. This suggests repurposing these kinase inhibitors for treating inflammatory and ischemic diseases.
Area of Science:
- Molecular Biology
- Cellular Biology
- Pharmacology
Background:
- Necroptosis is a programmed cell death pathway crucial in various physiological and pathological conditions.
- Key mediators include Receptor-Interacting Protein (RIP)1, RIP3, and mixed-lineage kinase domain-like protein (MLKL).
- Dysregulation of necroptosis is implicated in numerous human diseases.
Purpose of the Study:
- To review evidence on anticancer kinase inhibitors affecting necroptosis signaling.
- To explore the potential of drug repositioning for necroptosis-related pathologies.
Main Methods:
- Literature review of studies investigating kinase inhibitors and necroptosis.
- Analysis of existing data on multi-targeting kinase inhibitors with anti-necroptotic activity.
Main Results:
- Several anticancer kinase inhibitors (e.g., Dabrafenib, Vemurafenib, Sorafenib) demonstrate anti-necroptotic effects.
- These drugs interfere with critical components of the necroptosis signaling cascade.
Conclusions:
- Anticancer kinase inhibitors show potential for repurposing beyond cancer treatment.
- These therapeutics may be valuable for managing necroptosis-associated conditions like ischemic and inflammatory diseases.
Related Concept Videos
01:26Targets for Drug Action: Overview
10.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.5K
01:29Pharmacogenomics: Identification of New Drug Targets
3
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
3
01:24Modified-Release Drug Delivery Systems: Site-Targeted
4
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
4
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
2
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
2
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
4
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
4
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
7
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
7